AlphAIalphai — Financial news for AI agents
investing.comAUG 312 min read$TENX

Why is Tenax Therapeutics stock volatile today?

Tenax Therapeutics (TENX) stock rose 3.8% in pre-market trading after presenting additional Phase 3 trial data at the European Society of Cardiology Congress. The data showed favorable treatment effects for TNX-103 in patients with severe pulmonary hypertension due to heart failure. Several Wall Street firms initiated coverage with Buy ratings and price targets of $35-$40. The company has $118 million in cash, providing a runway through Q2 2028.

Original reporting
investing.com
Published Aug 31, 2026, 10:11 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 31, 2026, 10:22 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefTechnology
Primary signal
$TENX
Bullish
high confidence
Mentioned
$TENX
Relevance
9/10
alphai data visualization · based on investing.com
Decision brief

The 30-second read

$TENXBullishHigh
01

Why it matters

The Phase 3 LEVEL data provide the first robust efficacy signal, prompting analyst coverage and a modest price rally.

02

Market read

Fresh clinical data drive a short‑term price move and may set a new valuation baseline for the company.

03

What to watch

Regulatory review timelines and potential competition from other HFpEF candidates could temper upside.

Relevance 9/10Novelty 9/10Timing: pre‑open today

Background

Tenax Therapeutics is a Nasdaq‑listed biotech developing levosimendan for PH‑HFpEF.

Company-level read

Ticker impact

$TENXBullishHigh confidence
Context

Tenax Therapeutics stock rose 3.8% in pre‑open trading after fresh Phase 3 LEVEL data were presented at the ESC Congress.

Expected impact

Expect continued upside pressure in intraday trading, potentially testing recent resistance around $38.

Evidence & confidence

The data address a major unmet need (PH‑HFpEF) and are backed by new analyst initiations with $35‑$40 price targets.

Market effects

Sector

The data could lift sentiment across the pulmonary‑hypertension biotech space.

Regional

European cardiology conference exposure may attract European investors to TENX.

Global

Positive trial results may influence global investors seeking exposure to HFpEF therapies.

Counterpoint

What could challenge this read

If the trial endpoints are not clinically meaningful, the stock could face a pull‑back despite short‑term hype.

Key entities

  • company
    Tenax Therapeutics

    Biotech developer of TNX‑103 (oral levosimendan).

  • organization
    European Society of Cardiology

    Host of the conference where data were presented.

Read at source← All news

Related articles

AUG 29
$TENXMedAI 8/10

Tenax Therapeutics Presents Additional Phase 3 LEVEL Data Showing TNX-103 Benefits in PH-HFpEF Patients With Lower Baseline Walk Distance

Tenax Therapeutics (TENX) presented additional Phase 3 LEVEL trial data showing TNX-103 improved 6MWD, NT-proBNP, and RVSP in PH-HFpEF patients with lower baseline walk distance. The company plans to enrich the LEVEL-2 population based on these results. TNX-103 showed a 26.3m 6MWD improvement, 47% NT-proBNP reduction, and 4.9 mmHg RVSP reduction vs. placebo in this subgroup.

quiverquant.com3 min
AUG 29
$TENXMedAI 8/10

Tenax Therapeutics Announces Presentation of Phase 3 LEVEL Results in Late-Breaking Scientific Sessions at ESC Congress 2026

Tenax Therapeutics presented Phase 3 LEVEL trial results at ESC Congress 2026. TNX-103 showed significant improvements in patients with PH-HFpEF and baseline 6MWD below 333 meters, including a 26.3m walk distance improvement, 47% NT-proBNP reduction, and 4.9 mmHg RVSP reduction. The company plans to enrich the population for the next study.

finance.yahoo.com2 min
AUG 11
$TENXMed

A Wild Day In Biotech

Biotech stocks moved sharply after clinical and guidance updates. Tenax Therapeutics (TENX) fell nearly 90% after its Phase 3 LEVEL trial of TNX-103 missed primary and key secondary endpoints. AbCellera Biologics (ABCL) rose on Phase 2 results for ABCL635 in menopausal vasomotor symptoms. 10x Genomics (TXG) gained after raising full-year revenue guidance and citing strong early Atera demand.

zerohedge.com6 min
AUG 11
$TENXHighAI 9/10

Tenax Thera tanks on Phase III trial miss for TNX-103 in PH-HFpEF

Tenax Therapeutics (Nasdaq: TENX) shares fell about 90% to $1.38 after it reported Phase III LEVEL trial top-line results for TNX-103 (oral levosimendan) in PH-HFpEF. The trial did not meet the primary endpoint of improving 6-minute walk distance versus placebo, nor a key secondary endpoint on Kansas City Cardiomyopathy Questionnaire symptom score, according to the company.

thepharmaletter.com2 min
AUG 11
$TENXMed

Tenax LEVEL Trial Misses Primary Goal, but Subgroup Data Bolsters Levosimendan Case

Tenax reported its Phase III LEVEL trial of oral levosimendan missed the primary endpoint. The six-minute walk improvement versus placebo was 3.5 meters but not statistically significant, and the quality-of-life endpoint also failed. Subgroup and biomarker results suggested larger benefits in higher-risk patients. Tenax will consult the FDA and EMA and may adjust LEVEL-2 or run a new study.

yahoo.com2 min